Table 3.

Secondary outcomes and 14-day follow-up

		Levetiracetam (n=152)	Phenytoin (n=134)	Relative risk (95% CI)	p value
Secondary outcomes
Need for further anticonvulsants*		57 (37·5%)	50 (37·3%)	1·01 (0·74–1·36)	0·97
	Need for further anticonvulsants for the presenting convulsive status epilepticus†	24 (15·8%)	20 (14·9%)	1·06 (0·61–1·83)	0·84
	Need for further anticonvulsants for a subsequent seizure (within 24 h)†‡	14 (9·2%)	17 (12·7%)	0·72 (0·37–1·40)	0·33
RSI to terminate an ongoing seizure		44 (30·0%)	47 (35·1%)	0·83 (0·59–1·16)	0·27
Admission to critical care		97 (63·8%)	72 (53·7%)	1·19 (0·97–1·45)	0·08
Serious adverse reaction		0	2 (1%)§	..	..
14-day follow-up
Discharged from hospital		145 (95%)	130 (97%)	..	..
Readmitted to hospital		12 (8%)	10 (7%)	..	..
Patient died		1 (<1%)	1 (<1%)	..	..
Organ failure		1 (<1%)	0	..	..

Data are n (%) or relative risk (95% CI). RSI=rapid sequence induction.

^*Includes all instances of further anticonvulsant being given in following 24 h, including for the presenting seizure, subsequent seizures, or for prophylaxis.

^†Post-hoc analysis; assessment conducted without knowledge of the allocated intervention.

^‡Excludes nine participants with unavailable data.

^§Two events in one participant, one of which was a suspected unexpected serious adverse reaction.